NCT03738111撤回1 期
A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
Lee's Pharmaceutical Limited0 个研究点开始时间: 2018年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 主要终点
- Maximum Tolerated Dose
研究概览
简要总结
This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults ≥ 18 years of age at screening;
- •Life expectancy ≥ 3 months;
- •Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1;
- •Subjects must have histologically confirmed locally advanced or metastatic hepatocellular carcinoma (HCC) and have tumor that is refractory to or progressive after sorafenib treatment. Or the subjects are intolerable to sorafenib.
- •Prior local therapy to tumor (e.g. surgery, radiofrequency ablation, percutaneous ethanol injection, chemo-embolization, radiotherapy) is allowed provided that there is a target lesion not subjected to local therapy and/or disease progression has been documented in the target lesion subjected to local therapy. The treatment must be completed at least 4 weeks and patient has recovered from all the acute toxicities of that treatment.
- •At least 28 days, or at least 5 half-lives (whichever is shorter), since last systemic therapy (i.e., chemotherapy, targeted therapy, immunotherapy) before the first dosing of TG02, and have recovered from any clinically significant toxicity associated with such treatment;
- •HCC subjects must be of Child-Pugh class A (not amenable to or refractory to locoregional therapy). Subjects with HCC associated with hepatitis B virus must be receiving adequate antiviral therapy.
- •Must have at least 1 measurable lesion per RECIST 1.1 and evidence of disease progression since the last anti-tumor therapy.
- •Adequate hematologic, renal and hepatic function:
- •White Blood Cells ≥2000/uL Neutrophils ≥1500/uL Platelets ≥75,000/uL Hemoglobin ≥9.0g/dL (may have been transfused) Creatinine ≤2mg/dL Aspartate Aminotransferase (AST) <5 x upper limit of normal (ULN) alanine aminotransferase (ALT) <5 x upper limit of normal (ULN) Bilirubin ≤2 x ULN (except subjects with Gilbert's syndrome, who must have total bilirubin <3.0mg/dL) INR ≤1.5
- •Persistent clinically significant toxicities from prior chemotherapy must be ≤ grade
- •Ability to take oral medicine.
- •Negative urine pregnancy test at the time of first dose for women of child bearing potential (WOCBP). For men and WOCBP, adequate contraception must be used throughout the study. For this study, acceptable methods of contraception include a reliable intrauterine device or a spermicide in combination with a barrier method. Hormonal forms of birth control (oral, implantable, or injectable) may only be used if combined with a barrier method.
- •Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
排除标准
- •Past liver transplantation.
- •Uncontrollable hepatic encephalopathy or ascites.
- •Congestive heart failure (New York Heart Association Class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, and myocardial infarction within 6 months prior to first dose.
- •Screening ECG with a prolonged QTc interval (males: >450ms; females: >470ms) as calculated by the Fridericia correction formula despite balancing of electrolytes and/or discontinuing any drugs known to prolong QTc interval.
- •Concurrent severe or uncontrolled medical disease (e.g., active systemic infection, diabetes, hypertension, coronary artery disease) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
- •Symptomatic CNS or brain metastases.
- •Psychiatric illness/social situations that would limit compliance with study requirements.
- •Prior or second malignancy, except non-melanoma skin cancer, completed resected cervical or prostate cancer (with prostate-specific antigen (PSA) of less than or equal to 0.1ng/ml), or other cancer for which the subjects has received curative therapy at least 3 years prior to study entry.
- •Patient with pleural effusions requiring thoracentesis or ascites requiring paracentesis.
- •Acute hepatitis.
- •The subject is receiving an investigational drug, has an investigational device in place or has participated in an investigational drug or device study within 30 days prior to screening.
- •Pregnant or nursing.
- •History of drug abuse and taking drugs (such as marijuana, cocaine, opiates, benzodiazepines, amphetamines, barbiturates).
- •History of addicted to alcohol within 6 months before the study which defines as an average weekly intake of greater than 14 units (one unit=17.7ml ethanol, which is equivalent to 357ml beer with 5% alcohol content or 44ml spirits with 40% alcohol content or 147ml wine with 12% alcohol content).
- •Subjects who, in the opinion of the investigators, should not participate in the study.
研究组 & 干预措施
TG02 Citrate
Experimental
TG02 citrate capsules given orally.
干预措施: TG02 Citrate (Drug)
结局指标
主要结局
Maximum Tolerated Dose
时间窗: 28 days
To assess the number of patients with dose-limiting toxicities (DLT) and the dose of TG02 citrate that can be safely given to patients with advanced hepatocellular carcinoma.
次要结局
- Adverse Event(up to 12 months)
- Objective Response Rate, with respect to RECIST version 1.1(Up to 12 months)
- Progression Free Survival(At progression, up to 12 months)
- Overall Survival(At death, up to 12 months)
研究者
相似试验
已完成
1 期
Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) PatientsNon-small Cell Lung CancerNCT00569114Tragara Pharmaceuticals, Inc.45
已完成
1 期
A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular DegenerationNeovascular Age-related Macular DegenerationNCT03814291Innovent Biologics (Suzhou) Co. Ltd.31
已完成
1 期
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological MalignanciesALLBlast CrisisMDSMultiple MyelomaAMLNCT01204164Tragara Pharmaceuticals, Inc.120
已完成
1 期
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult ParticipantsHIV InfectionsNCT06033547ViiV Healthcare56
招募中
1 期
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 MutationSolid TumorNCT03781219Shanghai Kechow Pharma, Inc.45